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ABSTRACT 
 
 
 
 
 Drug eluting stent is a stent coated with an anti-proliferative drug to prevent 
in-stent restenosis in blood vessels.  Although this stent is superior to the bare stent, 
another post-stenting complication called late thrombosis, occurs as a result of late 
re-endotheliazation.  Therefore, this project was aimed to develop a drug eluting 
coating with ginseng extract that contained active ingredients of ginsenosides Rg1 
and Re, proven to not only inhibit the proliferation of vascular smooth muscle cells 
but also to promote the growth of vascular endothelial cells.  In this project, poly 
(lactic-co-glycolic) acid (PLGA) matrix was incorporated with ginseng extract at 
different ratios: 10%, 30% and 50% (w/w).  The gelation solvents were then coated 
on a stainless steel 316L, a substrate, by a dip coating technique.  The coatings were 
characterized by attenuated total reflectance-Fourier transform infrared spectroscopy 
(ATR-FTIR), scanning electron microscopy (SEM) and contact angle analyses while 
the drug release profile was studied through one month immersion tests and analyzed 
by a mass spectrometry instrument (Q-TOF LC-MS).  The FTIR analyses confirmed 
that the coatings were composed of ginseng and PLGA.  The SEM images showed 
that a full coverage and even coating was found on the 30% sample.  Higher ratio of 
PLGA caused higher hydrophobicity but not as high as the bare substrate.  The 
immersion study showed that all PLGA concentrations undergoes initial burst release 
dependent on the concentrations.  The release mechanism for the 30% and 50% 
samples was a combination of diffusion and swelling-controlled of PLGA whereas 
the release mechanism for the 10% sample was a Fickian diffusion.  The optimum 
coating was found on the 30% sample as it demonstrated acceptable wettability, even 
coating coverage and controlled release through the PLGA swelling.  The ginseng-
PLGA coating by a dip coating technique is practicable and it can be used as a drug 
eluting coating for stent application. 
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ABSTRAK 
 
 
 
 
 Sten pembebasan ubat ialah sten yang dilapisi dengan ubat anti-pertumbuhan 
untuk menghalang penyempitan kembali sten di dalam pembuluh darah. Walaupun 
sten ini lebih berkesan berbanding sten logam tanpa salutan, berlakunya komplikasi 
lain selepas implantasi yang dikenali sebagai kelewatan thrombosis, kesan kepada 
kelewatan pertumbuhan semula endotelial. Oleh itu, projek ini bertujuan untuk 
menghasilkan salutan pembebasan ubat dengan ekstrak ginseng yang mengandungi 
ramuan aktif ginsenoside Rg1 dan Re, yang terbukti bukan sahaja menghalang 
pertumbuhan sel otot licin vaskular tetapi juga menggalakkan pertumbuhan sel 
endotelial vaskular. Dalam kajian ini, matrik asid poli(laktik-ko-glikolik) (PLGA) 
dilarutkan dengan ekstrak ginseng pada pelbagai nisbah: 10%, 30% dan 50%  (w/w). 
Pelarut gel tersebut kemudiannya disalut ke atas substrat keluli tahan karat 316L 
menggunakan teknik penyalutan celup. Salutan dianalisis menggunakan jumlah 
pantulan pengecilan-spektroskopi pengubah inframerah Fourier (ATR-FTIR), 
mikroskop pengimbas elektron (SEM) dan analisis sudut sentuhan manakala profil 
pembebasan ubat dikaji melalui ujian rendaman selama sebulan dan dianalisis oleh 
instrumen spektrometri berat (Q-TOF LC-MS). Analisis ATR-FTIR mengesahkan 
bahawa salutan  tersebut mengandungi ginseng dan PLGA. Imej SEM menunjukkan 
bahawa salutan adalah menyeluruh dan sama rata pada sampel 30%. Nisbah PLGA 
yang tinggi menyebabkan peningkatan sifat hidrofobik namun tidak setinggi substrat 
tanpa salutan. Ujian pembebasan ubat menunjukkan bahawa semua nisbah PLGA 
melalui pembebasan pecah pada permulaan ujian, bergantung kepada kepekatan. 
Mekanisma pembebasan untuk sampel 30% dan 50% ialah gabungan serapan dan 
pengembangan berkadar PLGA manakala mekanisma pembebasan untuk sampel 
10% ialah serapan Fick. Lapisan optimum dikenalpasti pada sampel 30% kerana ia 
menunjukkan kebolehbasahan yang baik, salutan menyeluruh dan pembebasan 
terkawal melalui pengembangan PLGA. Penyalutan ginseng-PLGA menggunakan 
kaedah penyalutan celup adalah praktikal dan boleh digunakan sebagai salutan 
pembebasan ubat untuk aplikasi sten. 
 
vii	  
 
TABLE OF CONTENTS 
 
 
 
 
CHAPTER TITLE PAGE 
 
 DECLARATION ii 
 DEDICATION iii 
 ACKNOWLEDGEMENT iv 
 ABSTRACT v 
 ABSTRAK vi 
 TABLE OF CONTENTS vii 
 LIST OF TABLES x 
 LIST OF FIGURES xi 
 LIST OF ABBREVIATIONS xiii 
 LIST OF SYMBOLS xvii 
 LIST OF APPENDICES xix 
   
1 INTRODUCTION 1 
 1.1    Background of study 1 
 1.2    Problem statement 4 
 1.3    Objectives of the study 5 
 1.4    Scopes of the research 5 
          1.4.1  Sample preparation 6 
          1.4.2  Coating characterization 6 
          1.4.3  Coating drug release profile 6 
 1.5    Significance of the study 6 
   
2 LITERATURE REVIEW 8 
viii	  
 2.1    Introduction 8 
 2.2    Physiology of the cardiovascular system 8 
 2.3    Anatomy of blood vessels 9 
 2.4    Atherosclerosis 11 
          2.4.1  Atherogenesis 12 
 2.5    Overview of drug eluting stent: Commercial  
designs and coating method 
14 
          2.5.1  Commercial stents designs and problems 14 
                    2.5.1.1 Bare metal stent inorganic coating 15 
                    2.5.1.2 First generation of drug eluting   
stent 
16 
                    2.5.1.3 Second generation of drug eluting 
stent 
17 
                    2.5.1.4 Other drug eluting coating 
designs 
18 
                    2.5.1.5 Summary of drug eluting stent  
                               problems 
21 
          2.5.2  Stent coating methods 23 
                    2.5.2.1 Dip coating 24 
 2.6    Ginseng extract medicinal potentials on  
         cardiovascular disease 
25 
          2.6.1  Ginseng active ingredients 25 
          2.6.2  Ginsenoside properties as drugs for stent 27 
                    2.6.2.1 Ginseng anti-proliferative 
property 
29 
                    2.6.2.2 Ginseng protective property 34 
                    2.6.2.3 Ginseng antithrombotic property 35 
 2.7    Drug release by PLGA 36 
          2.7.1  Empirical mathematical models of drug 
release mechanism 
38 
   
3 RESEARCH METHODOLOGY 41 
 3.1    Materials 41 
ix	  
          3.1.1  Coating materials 41 
          3.1.2  Chemicals and reagents 41 
 3.2    Methodology 42 
          3.2.1  Sample preparation 42 
                    3.2.1.1 Substrate pre-treatment 42 
                    3.2.1.2 Coating preparation 44 
                    3.2.1.3 Dip coating process 45 
          3.2.2  Coating characterization 46 
                    3.2.2.1 Attenuated total reflectant Fourier  
                               transform infrared spectroscopy  
                               (ATR- FTIR) 
46 
                    3.2.2.2 Scanning electron microscopy 
                              (SEM) 
46 
                    3.2.2.3 Contact angle 46 
          3.2.3  Drug release profile 47 
                    3.2.3.1 Immersion test 47 
                    3.2.3.2 Liquid chromatography-mass  
                               spectroscopy analysis (LC-MS  
                               TOF) 
47 
                    3.2.3.3 Mathematical model analyses 48 
   
4 RESULTS AND DISCUSSIONS 49 
 4.1    The effect of PLGA concentration on coating    
         properties. 
49 
 4.2    Coating characterization 51 
          4.2.1  Coating composition  51 
          4.2.2  Coating morphology and wettability 54 
 4.3    Drug release of coating 58 
          4.3.1 Drug release study 58 
   
5 CONCLUSION 67 
REFERENCES 69 
Appendices A-B      83-85 
 
x	  
 
LIST OF TABLES 
 
 
 
 
TABLE  TITLE 
 
PAGE 
2.1 Recent DES coating technologies based on literatures 19 
2.2 Different techniques of stent coating 23 
2.3 Summary of anticancer activities of ginsenosides 30 
3.1 Coating solution preparation 44 
3.2 Modification of dip coater settings 45 
3.3 Mass spectrometry settings 48 
4.1 Coating properties of PLGA concentration at 10, 30 
and 50% (w/w). 
50 
4.2 Coating thickness and pH value after a month of 
immersion 
59 
4.3 Release kinetics of ginseng 66 
5.1 Limitations and recommendations of the study 68 
B EDX images of halites presence on coating after 30 
days immersion at 30× magnification 
88 
 
 
 
 
 
 
 
 
 
xi	  
 
LIST OF FIGURES 
 
 
 
 
FIGURE TITLE 
 
PAGE 
2.1 Layers in the walls of artery.  10 
2.2 Atherogenosis stages in blood vessels. 12 
2.3 Formation of atherosclerosis plaque.  13 
2.4 The first and second generation of DES designs first 
approved by FDA. 
18 
2.5 Timeline of bare metal and drug eluting stent 
problems after their implantation. 
22 
2.6 Dip coating process. 24 
2.7 Pictures of asian and american ginseng plants and 
roots. 
26 
2.8 Chemical structure of ginsenoside group. 28 
2.9 Several possible molecular mechanisms of 
ginsenoside against cancerous cells. 
31 
2.10 Drugs in commercial DES and ginsenoside cell cycle 
arrest mechanism. 
33 
2.11 Illustration of true release mechanism.  37 
3.1 Dimension of 316L stainless steel foil. 42 
3.2 Substrate pre-treatment processes 43 
4.1 ATR-FTIR spectra of  the controls. 52 
4.2 ATR-FTIR spectra of the samples with different 
PLGA concentration. 
53 
4.3 SEM images of coating at 250× magnification. 55 
4.4  Contact angle analysis of different PLGA 56 
xii	  
concentration. 
4.5 Drug release profile analysis of ginsenosides Rg1 and 
Re. 
62 
4.6 Drug release kinetic analysis of ginsenosides Rg1 and 
Re 
63 
4.7 Higuchi release kinetics of ginsenosides 64 
4.8 Hixson-Crowell model release kinetics of 
ginsenosides 
64 
4.9 Korsmeyer – Peppas kinetic release of ginsenosides 65 
B.1 Water contact angle images 86 
B.2 Coating thickness on stainless steel 316L images 87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii	  
 
LIST OF ABBREVIATIONS 
 
 
 
 
AMPK -	   5’AMP-activated protein kinase 
AP -	   Activator protein 
ASK1 -	   Apoptosis signal-regulating kinase 
ATR-FTIR - Attenuated total reflectance-Fourier transform infrared 
spectroscopy 
bFGF -	   Basic fibroblast growth factor 
BMS - Bare metal stent 
CDKs -	   Cyclin-dependent kinases 
CE - Conformité Européenne 
cGMP -	   Cyclic guanosine monophosphate 
Co-Cr - Cobalt-chromium 
CVD - Cardiovascular diseases 
DES - Drug eluting stent 
DMEM - Dulbecco’s Modified Eagle’s Medium 
DNA - Deoxyribonucleic acid 
EC - Endothelial cells 
EDRF -	   Endothelium-derived relaxing factor 
EDX - Energy disperse X-ray 
EGF -	   Epithelial growth factor 
eNOS - Endothelial nitric oxide synthase 
ERK -	   Extracellular signal-regulated kinase 
WHO - World Health Organization 
FDA - United States Food and Drug Administration 
GR - Glucocorticoid receptor 
HAEC -	   Human aortic endothelial cells 
xiv	  
HCl - Hydrochloric acid 
HUVEC - Human umbilical vein endothelial cells 
IAP -	   Inhibitory apoptotic protein 
IL-1 - Interleukin 1 
iNOS -	   Inducible nitric oxide synthase 
JAK - Janus kinase 
JNK -	   c-Jun N terminal kinase 
KCl - Potassium chloride 
LST - Late stent thrombosis 
MAPK - Mitogen activated protein kinase 
MDM2 -	   Murine double minute-2 
MMP - Matric metalloproteinase 
mTOR - Mammalian target rapamycin 
NaCl - Sodium chloride 
NO - Nitric oxide 
NRF2 -	   Nuclear factor-erythroid 2-related factor-2 
OH - Hydroxyl 
OG - Ongoing 
oxLDL - Oxidize lipoprotein 
PBMA - Poly(n-butyl methacrylate) 
P. ginseng - Panax ginseng 
P.notoginseng - Panax notoginseng 
P. quinquefolius - Panax quinquefolius 
PAI-1 - Plasminogen activator inhibitor-1 
PC - Phosphorylcholine 
PCI - Percutaneous coronary intervention 
PCL - Polycaprolactone acid 
PDLLA - Poly (D, L-lactide) acid 
PDGF -	   Platelet-derived growth factor 
PDGF-BB - Platelet-derived growth factor-BB 
PGA - Polyglycolic acid 
PKA -	   Protein kinase 
PKC - Protein kinase C 
xv	  
PLA - Polylactic acid 
PLGA - Poly (lactic-co-glycolic) acid 
PPD - Protopanaxadiol 
PPT - Protopanaxatriol 
Pt-Cr - Platinum-chromium 
PVP - Polyvinylpyrrolidone 
P13K/Akt - Phosphatidylinositol 3-kinase/ protein kinase B 
Q-TOF LC-MS - Quadrupole time-of-flight liquid chromatography-mass 
spectrometry 
SEM - Scanning electron microscopy 
SIBS - Poly(styrene-b-isobutylene-b-styrene); 
SiRNA - Small interfering ribonucleic acid 
SNAP -	   S-nitroso-N-acetylpenicillamine 
SNP -	   Sodium nitroprusside 
SOD-1 -	   Superoxide dismutase-1 
SS - Stainless steel 
STAT - Signal tranducers and activators of transcription family 
t-PA - Tissue-type plasminogen activator 
TRAIL-R1/DR4 -	   Tumor necrosis factor-related apoptosis-inducing 
ligand/death receptor 4. 
VEGF - Vascular endothelial growth factor 
VSMC - Vascular smooth muscle cells 
NF-κB -	   Nuclear factor κB 
TNF-α - Tumor Necrosis factor alpha 
Ca2+ - Calcium ion 
CaCl2 - Calcium chloride 
C2H3N - Acetonitrile 
CH2O2 - Formic acid 
C3H8O3 - Glycerol 
C2H6O4S 
(DMSO) 
- Dimethyl sulfoxide 
(HOCH2)3 CNH2 - Tris-hydroxymethyl aminomethane 
H3PO4 - Phosphoric acid 
xvi	  
K2 HPO4.3H2O - di-potassium hydrogen phosphate trihydrate 
MgCl2.6H2O - Magnesium chloride hexahydrate 
NaHCO3 - Sodium hydrogen carbonate 
Na2SO4 - Sodium sulfate 
   
   
 
 
 
 
 
 
 
 
 
xvii	  
 
LIST OF SYMBOLS 
 
 
 
 
o - Degree 
= - Equal 
< - Less than 
% - Percentage 
A	 - Ampere 
dL/g - Deciliter per gram 
g - Gram 
kV - Kilovolt 
L/min - Liter per minute 
mg - Milligram 
mg/L - Milligram per liter 
mm - Millimeter 
mL - Milliliter 
mm/min - Millimeter per minute 
mL/min - Milliliter per minute 
mPa.s - Millipascal seconds 
m/z - Mass-to-charge ratio 
V - Volt 
w/w - Mass per mass 
w/vol - Mass per volume 
α - Alpha 
β - Beta 
κ - Kappa 
µm - Micrometer 
µmol/L - Micromole per liter 
xviii	  
µ? - Microliter 
oC - Degree celcius 
cm2 - Square centimeter 
cm-1 - Per centimeter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xix	  
 
LIST OF APPENDICES 
 
 
 
 
APPENDIX TITLE	  
 
PAGE 
A Characteristic  infrared  absorption of functional 
groups. 
83 
B Water contact angle and coating thickness images and 
presence of halites on coating. 
85 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
 
CHAPTER 1 
 
 
 
 
INTRODUCTION 
 
 
 
 
1.1 Background of the study 
 
 
 In the South Asia region including Malaysia, both morbidity and mortality 
caused by the cardiovascular disease (CVD) is high and it is expected to increase 
even more due to high prevalence of diabetes, hypertension and smoking [1].  
Statistics from the Ministry of Health Malaysia 2013 showed that diseases of the 
circulatory system are the number one cause of death in the public and private 
hospitals with 24.38% and 27.73% of total deaths, respectively [1].  The Global 
Atlas on cardiovascular disease prevention and stroke report stated that over 80% of 
CVD deaths take place in low and middle income countries [2].  Besides, the World 
Health Organization (WHO) predicted more than 23.3 million of people would die 
annually from CVDs by 2030 [3].  With increasing number of cases, especially in the 
low and middle income countries, it is vital to take active prevention and offer more 
affordable treatment of CVDs. 
 
 
 Atherosclerosis is a type of arteriosclerosis that leads to several CVDs such 
as peripheral arterial disease, coronary heart disease, stroke and heart attack [3].  
This condition caused by an accumulation of fatty plaque and cholesterol blockage 
	   2 
that later thicken and harden blood vessels [3].  One of the current most used 
treatments for CVD is the Percutaneous Coronary Intervention (PCI) [2].  This non-
surgical procedure involves insertion of a balloon with or without stent through 
catheter wires at the side of a narrowed blood vessel.  Stent is a small metal mesh 
tube that acts as a scaffold inside narrow weak blood vessels [4].  There are three 
types of coronary stents: bare metal (BMS), drug eluting (DES), and bioresorbable 
scaffold or biodegradable stent [5].  All stents and their accessories are expensive as 
they are imported from United States of America, Europe, Japan and China due to no 
local manufacturer.  According to the chief executive officer of National Heart 
Institute, Tan Sri Dr. Robaayah Zambahari, the cost for BMS in Malaysia is RM 
2000 whereas the DES cost is between RM 6000 and RM 8000 [6].  
 
 
 High-pressure balloon inflation during PCI caused mechanical stress and 
denudation of the endothelium layer in the blood vessel wall [7].  An inflammatory 
response at the lesion wall started and progressed earlier at first six weeks than the 
recovery of the endothelial layer that took approximately three months to complete 
after stenting [7].  This inflammation will cause rapid proliferation of vascular 
smooth muscle cells (VSMC) and lead to in-stent restenosis [7].  Drug eluting stent 
is the second generation of stent, coated with drugs targeted to prevent restenosis by 
stopping the proliferation of VSMC [8].  However, it has several limitations such as 
delayed endotheliazation caused by rapid release of anti-proliferative drug and 
polymer hypersensitivity which leads to late thrombosis [8].  Because of these 
problems, there are tremendous works on how to develop a multifunctional drug and 
less sensitive stent design. 
 
 
 Most permanent implants are made of stainless steel 316L because of its 
biocompatibility, less toxicity and strong structure [9].  Besides stent, the stainless 
steel 316L is also used to make cranial plates, orthopedic fracture plates, dental 
implants, spinal cords, joint replacement prostheses catheters and other surgical tools 
[9].  This low carbon steel and cobalt chromium are traditional materials used to 
fabricate BMS, the first generation of invented stent [8].  In the human body, the 
corrosion of stainless steel 316L will release iron, chromium and nickel ions where 
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incontrollable amount of these ions can act as allergens and carcinogens [9].  The 
major problem of BMS is the inflammation reaction of human body to this foreign 
matter that cause rapid growth of VSMC [8].  Thus, the coating of permanent metal 
implants is necessary to lower the response and the effect of body inflammation at 
early stage of implantation until the metal is no longer presumed as a foreign body. 
 
 
 Metallic implants’ drug coating used biodegradable polymers to control the 
drug release.  Drugs were incorporated into polymer matrix by several techniques 
such as nano-precipitation, emulsion-diffusion, double emulsification, emulsion-
coacervation, polymer-coating and layer-by-layer methods [10].  The polymers 
hydrolyzed to release drugs and later excreted from the body.  Several polymers used 
in DES as a coating material are polylactic acid (PLA), polyglycolic acid (PGA), 
poly(D,L-lactide) acid (PDLLA), poly(lactic-co-glycolic) acid (PLGA) and 
polycaprolactone acid (PCL) [11].  Poly(lactic-co-glycolic) acid is a copolymer of 
lactic and glycolic acid that degrades by hydrolysis of its ester linkages in the 
presence of water and it will be removed by renal excretion.  Since its application has 
been approved by the United States Food and Drug Administration (FDA), PLGA is 
used in many biomedical device applications such as graft, sutures, implants and 
nanoparticle [12] 
 
 
 Plants are utilized to alleviate disease since centuries ago.  The WHO 
estimated that 80% of people worldwide rely on herbal medicine for some parts of 
their primary health care [13].  Nowadays, researchers are emphasizing on evaluating 
the effects of phytochemicals from the active ingredients of herbs that play major 
roles in their therapeutic effects on various diseases including CVD.  Ginseng root 
has been used for over 5000 year ago as a medicinal herb in traditional Chinese 
medicine and still being used as a health supplement worldwide [14].   
 
 
Ginsenoside is the active ingredient of Asian ginseng, scientifically known as 
Panax Ginseng, and has been studied intensively for its effect on cardiovascular 
system such as improving circulation and antioxidant activity, modulating vascular 
	   4 
function, improving cardiac function, inhibiting platelet aggregation, and adjusting 
lipid profile [14].  Certain types of ginsenosides such as Rb1, Rg1 and Rg3 are able 
to overcome the problem of DES by inhibiting the proliferation of VSMC and 
promoting the growth of endothelial cells (EC) in vitro and in vivo [14,18], making 
them suitable to be used as a herbal drug to treat post-stenting problem.  Despite 
some significant scientific findings of ginsenosides and their effects on CVD, 
ginseng coating for cardiovascular implant, specifically on stent, has not yet been 
reported.  Therefore, this project was aimed to develop a drug eluting coating on 
stainless steel 316L by incorporating ginseng extract, a herbal medication that can 
addresses the drawbacks of current DES.  Poly(lactic-co-glycolic) acid was utilized 
as the main matrix to optimize and control the coating formation and ginseng release. 
 
 
 
 
1.2 Problem statement 
 
 
  Heart disease is still the main cause of death in Malaysia.  Drug eluting stent 
is currently a preferred stent for PCI because it reduced the proliferation of VSMC 
[6].  However, the technology has not been developed, locally, and the price of DES 
is three times higher than the BMS [6].  Therefore, there is a need to develop our 
own drug eluting coating as an alternative to the current over-price DES.  
 
 
 The current DES undertakes the BMS problem but it also has several 
drawbacks such as late endotheliazation and polymer hypersensitivity that later cause 
abnormal endothelial cells, local hypersensitivity and late thrombosis [8]. Several 
factors that caused late endotheliazation is the rapid release anti-proliferative drug 
that can arrests endothelial cells growth as shown in several clinical trials [8] and the 
usage of permanent, hydrophobic and biostable polymer.  New DES design together 
with several improvements on metal design and drug function that specific for 
VSMC and EC were developed but no multifunctional herbal-based drug was used as 
all drugs were derived synthetically. 
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  It can be concluded that, to develop our own drug eluting coating for stent, 
the coating must be able to release multifunctional drug, proven by many literatures 
to be anti-proliferative to VSMC yet harmless to EC, in a controlled manner by using 
a biocompatible polymer.  
 
 
 
 
1.3 Objectives of the study 
 
 
 This study aimed to develop a controlled release ginseng-PLGA drug eluting 
coating by a dip coating technique for stent application.  Fundamental experiments 
listed below were carried out to develop the coating: 
 
 
1. To determine optimize drug to polymer ratio that can produces adequate 
PLGA-ginseng coating on stainless steel 316L. 
 
2. To identify the physico-chemical properties of the PLGA-ginseng coating by 
identifying the coating composition using attenuated total reflectance-Fourier 
transform infrared spectroscopy (ATR-FTIR), coating morphology using 
scanning electron microscopy-energy dispersive X-ray (SEM-EDX) and 
wettability property using contact angle analysis 
 
3. To investigate the drug release mechanism of the PLGA-ginseng coating 
using mass spectrometry instrument (Q-TOF LC-MS) and five mathematical 
models. 
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1.4 Scopes of the research 
 
 
 The scope of this study was divided into three parts: sample preparation, 
coating characterization and coating drug release profile.  The sample preparation 
involved the pre-treatment of stainless steel 316L metal started with a cleaning and 
ended with an electropolishing process.  A coating solution with standard total 
concentration of PLGA and ginseng but with different polymer to drug ratio were 
made by dissolving them in dimethyl sulfoxide (DMSO), a solvent that can dissolve 
both, ginseng and PLGA.  The metals were coated with different ginseng to PLGA 
ratio by using a desktop dip coater.  The coatings were characterized to visualize the 
coating surface, coating coverage and coating thickness by SEM.  The coatings 
compositions were then characterized by ATR-FTIR and the wettability of the 
coatings was measured via contact angle analysis.  The coating were immersed in a 
complete cell medium Dulbecco’s Modified Eagle’s Medium (DMEM), mimicking 
the in vitro environment to observe the sustainability of the coating to release drug in 
a month.  The liquid chromatography – mass spectroscopy (Q-TOF LC-MS) was 
used to quantify the drug released.  Finally, the quantitative data were analyzed to 
best fit five mathematical models in determining the drugs release mechanisms.. 
 
 
 
 
1.5 Significance of the study 
 
 
 This study utilized the knowledge of ginsenosides’ properties that is anti-
proliferative to the smooth muscle cells and harmless to the endothelial cells based 
on reports in many literatures.  The novelty of this study is that, despite these known 
properties of ginsenosides, there was no attempt to coat ginseng on implant to use it 
for local delivery.  Acknowledging the healing properties of ginseng in preventing 
restenosis and late thrombosis, the study of ginseng coating on implant, generally, 
and in stent, especially, will provide an alternative to the current drug eluting coating. 
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 This fundamental research will show the capability to coat a herbal-based 
drug by using an easy and cost-effective coating technique called dip coating.  The 
characterization of this coating can be used to further optimize the coating quality 
and supports the idea of the possibility to coat herbal-based drug on a metal.  The 
drug release study of this coating will also help to illustrate the coating condition and 
its quality when immersed in a cell medium. 
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